Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA3038 Safety and PK in Healthy Adults
NCT06085053Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TQA3038 with Placebo (2 arms). Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) up to 85 days and Number of subjects with clinically significant abnormalities up to 85 days. Started Nov 2023; status: recruiting.
02
Drugs
TQA3038
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06085053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085053.